Research / Clinical Trials
Our practice offers clinical trials which help determine whether newly developed treatments are safe and effective in treating Multiple Sclerosis. These studies are important research tools for the developing new treatment options for this chronic disease. Clinical trials also provide patients with access to new treatment options and new therapies that are not offered to the general population.
As new technologies and therapeutic options become available, Hope Neurology Multiple Sclerosis Center utilizes clinical trials to provide innovative treatment options to our patients.
Clinical research studies provide patients with new medications and access to comprehensive disease management. By working closely with our pharmaceutical sponsors, we strive to improve the health, hope and well-being of our patients.
For more information on any of our studies, please call 865. 218.6222 and ask to speak with Brenda, Kim or Shannon or email us at email@example.com
Enrolling Clinical Trials:
· ALK8700-A301 – A Phase 3 Open-Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis
· ALK8700-A302 – A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
· Actelion AC-058B301 – A Multicenter, randomized, double-blind, parallel-group, active-controlled,superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis
· Asclepsios COMB157G2302 – A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
· CFTY720D2312 – A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
· IVSS OBS14379 – A prospective observational cohort study in adult patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA (alemtuzumab) infusions of the first treatment course
· MN30035 – An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Had a Sub-Optimal Response to an Adequate Course of Disease- Modifying Treatment
· PASS OBS13434 – A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis
· ProAct OBS14448 – A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA® Treatment In Patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modifying Therapy
· RPC01-1001 – A Phase 1, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple-Dose Pharmacokinetics and Pharmacodynamics of RPC1063 in Patients with Relapsing Multiple Sclerosis
· TG1101-RMS201 – A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis